On June 4, 2025, Synaptogenix, Inc. reported a private placement agreement to sell 5,500 shares of Series D convertible preferred stock and warrants for $5.5 million, with plans to acquire $10 million worth of Bittensor TAO cryptocurrency. Additionally, Dr. Daniel L. Alkon resigned as Chief Science Officer on the same date, continuing as a consultant to the Bryostatin Development Committee.